培美曲塞联合沙利度胺二线治疗晚期非小细胞肺癌的疗效观察  

Clinical observation of pemetrexed combined with thalidomide for the second-line treatment of advanced non-small cell lung cancer

作　　者：李冬雷[1] 杨惠卫 李冬杰[1] 王卫军[1] 马少林[1] 

机构地区：[1]河北省保定市第二中心医院肿瘤科,保定072750

出　　处：《中国肿瘤临床与康复》2014年第7期817-819,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨培美曲塞联合沙利度胺二线治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法选取60例NSCLC患者,随机分为试验组(32例)和对照组(28例)。试验组患者采用培美曲塞联合沙利度胺治疗,对照组患者采用培美曲塞单药治疗,分析两组患者的临床疗效和不良反应。结果试验组患者的中位无疾病进展时间(PFS)为6.5个月,对照组为3.0个月(P=0.006)。两组患者的中位总生存时间(OS)和不良反应发生率比较,差异无统计学意义(P>0.05)。结论培美曲塞联合沙利度胺可显著提高晚期NSCLC患者的中位PFS,值得临床推广应用。Objective To evaluate the clinical effects of pemetrexed combined with thalidomide for the second-line treatment of advanced non-small cell lung cancer （NSCLC）. Methods 60 patients with NSCLC were randomly divided into 2 groups. The control group was treated with pemetrexed, and the obser- vation group was treated with pemetrexed and thalidomide. The median progress free survival（ PFS）, overall survival （OS） and adverse effects of the two groups were compared. Results The median PFS of the obser- vation group prolonged 3.5 months than the control group （ P = 0. 006）, while the median OS and the ad- verse effects were consistent （ P 〉 O. 05 ）. Conclusion. Pemetrexed combined with thalidomide prolonged the median PFS, which can be clinically used in NSCLC.

关 键 词：癌 非小细胞肺 沙利度胺 培美曲塞 药物疗法 

分 类 号：R734.2[医药卫生—肿瘤]